140 related articles for article (PubMed ID: 28188897)
1. Survival biases lead to flawed conclusions in observational treatment studies of influenza patients.
Wolkewitz M; Schumacher M
J Clin Epidemiol; 2017 Apr; 84():121-129. PubMed ID: 28188897
[TBL] [Abstract][Full Text] [Related]
2. Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Wolkewitz M; Schumacher M
PLoS One; 2016; 11(9):e0160430. PubMed ID: 27583403
[TBL] [Abstract][Full Text] [Related]
3. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.
Viasus D; Paño-Pardo JR; Pachón J; Riera M; López-Medrano F; Payeras A; Fariñas MC; Moreno A; Rodríguez-Baño J; Oteo JA; Ortega L; Torre-Cisneros J; Segura F; Carratalà J;
Chest; 2011 Oct; 140(4):1025-1032. PubMed ID: 21415133
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Al Khuwaitir TS; Al Mamun A; Anovadiya AP; Azziz-Baumgartner E; Báez C; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Iglesias AL; Hoger PH; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Knight M; Kudo K; Kusznierz G; Kuzman I; Kwan AM; Amine IL; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Mayo-Montero E; McGeer A; Memish Z; Metan G; Mickiene A; Mikić D; Mohn KG; Moradi A; Nymadawa P; Oliva ME; Ozkan M; Parekh D; Paul M; Polack FP; Rath BA; Rodríguez AH; Sarrouf EB; Seale AC; Sertogullarindan B; Siqueira MM; Skręt-Magierło J; Stephan F; Talarek E; Tang JW; To KK; Torres A; Törün SH; Tran D; Uyeki TM; Van Zwol A; Vaudry W; Vidmar T; Yokota RT; Zarogoulidis P; ; Nguyen-Van-Tam JS
Lancet Respir Med; 2014 May; 2(5):395-404. PubMed ID: 24815805
[TBL] [Abstract][Full Text] [Related]
5. Immortal time bias in observational studies of time-to-event outcomes.
Jones M; Fowler R
J Crit Care; 2016 Dec; 36():195-199. PubMed ID: 27546771
[TBL] [Abstract][Full Text] [Related]
6. The use of antiviral agents for the management of severe influenza.
Smith JR; Ariano RE; Toovey S
Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
[TBL] [Abstract][Full Text] [Related]
7. Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study.
Lytras T; Mouratidou E; Andreopoulou A; Bonovas S; Tsiodras S
Clin Infect Dis; 2019 Nov; 69(11):1896-1902. PubMed ID: 30753349
[TBL] [Abstract][Full Text] [Related]
8. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
9. Debate on whether Tamiflu prevents flu deaths reignites after new analysis.
Hawkes N
BMJ; 2016 May; 353():i3077. PubMed ID: 27251383
[No Abstract] [Full Text] [Related]
10. Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.
Canadell L; Martín-Loeches I; Díaz E; Trefler S; Grau S; Yebenes JC; Almirall J; Olona M; Sureda F; Blanquer J; Rodriguez A;
Med Intensiva; 2015 May; 39(4):222-33. PubMed ID: 25107582
[TBL] [Abstract][Full Text] [Related]
11. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
Weber JT; Nicoll A; Bridges CB; Ciancio BC
BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
[No Abstract] [Full Text] [Related]
12. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.
Lackenby A; Moran Gilad J; Pebody R; Miah S; Calatayud L; Bolotin S; Vipond I; Muir P; Guiver M; McMenamin J; Reynolds A; Moore C; Gunson R; Thompson C; Galiano M; Bermingham A; Ellis J; Zambon M
Euro Surveill; 2011 Feb; 16(5):. PubMed ID: 21315056
[TBL] [Abstract][Full Text] [Related]
13. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with early hospital discharge of adult influenza patients.
Lee N; Chan PK; Choi KW; Lui G; Wong B; Cockram CS; Hui DS; Lai R; Tang JW; Sung JJ
Antivir Ther; 2007; 12(4):501-8. PubMed ID: 17668558
[TBL] [Abstract][Full Text] [Related]
15. Pandemic (H1N1) 2009 influenza in hospitalized children in Manitoba: nosocomial transmission and lessons learned from the first wave.
Fanella ST; Pinto MA; Bridger NA; Bullard JM; Coombs JM; Crockett ME; Olekson KL; Poliquin PG; Van Caeseele PG; Embree JE
Infect Control Hosp Epidemiol; 2011 May; 32(5):435-43. PubMed ID: 21515973
[TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Nguyen-Van-Tam JS; Nicholson KG
J Clin Virol; 2011 Feb; 50(2):183. PubMed ID: 21112812
[No Abstract] [Full Text] [Related]
17. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
18. Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
Chan PA; Connell NT; Gabonay AM; Westley B; Larkin JM; LaRosa SP; Chapin K; Mermel L
Clin Microbiol Infect; 2010 Oct; 16(10):1576-8. PubMed ID: 20218988
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Kashiwagi S
J Infect; 2009 Sep; 59(3):207-12. PubMed ID: 19619898
[TBL] [Abstract][Full Text] [Related]
20. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
